COMBINE FORCES WITH TYVERB

Tyverb is approved for use in combination with each of the three trusted agents below to maintain HER2 blockade1-7

Tyverb in combination with capecitabine

For patients with advanced or metastatic HER2-positive breast cancer with progression following prior therapy, which must have included anthracyclines and taxanes, and therapy with trastuzumab in the metastatic setting.1

Tyverb in combination with capecitabine

Tyverb in combination with an AI

For postmenopausal women with HER2-positive and hormone receptor-positive metastatic breast cancer, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.1

Tyverb in combination with an AI

Tyverb in combination with trastuzumab

For patients with hormone receptor-negative, HER2-positive metastatic breast cancer that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.1

Tyverb in combination with trastuzumab
Reference: 1. Tyverb® (lapatinib) Summary of Product Characteristics. Camberley, UK: Novartis Europharm Limited; 11 August 2015. 2. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii11-vii19. 3. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71. 4. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-543. 5. Montemurro F, Rossi V, Cossu Rocca M, et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer. 2012;118(1):17-26. 6. European Medicines Agency. Assessment report: Tyverb. Revised June 27, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000795/WC500147870.pdf. Accessed September 4, 2015. 7. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30(21):2585-2592.